CC-99677 Chemical Structure oral, covalent MK2 inhibitor - Bristol Myers Squibb, Princeton, NJ

oral, covalent MK2 inhibitor

Ph. II candidate in ankylosing spondylitis

from previously disclosed MK2 inhibitor and SBDD

Transl Res

Bristol Myers Squibb, Princeton, NJ

Context. CC-99677 (BMS) is an oral, covalent MAPK–activated protein kinase-2 (MK2) inhibitor being developed for autoimmune diseases. Although p38 is the most heralded member of the p38-MAPK signaling pathway,…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.